News

West Pharmaceutical Services recently announced it will phase out a product line at its Scottsdale facility by the end of September, resulting in 98 layoffs and related manufacturing work being shifted to other Becton, Dickinson and Co. locations. At the same time, the company’s push into higher-value products and Annex 1-related sterility upgrades is being tempered by cyber incident disruptions in its West Vantage segment and tariff- and commodity-driven cost pressures. We’ll now examine...

West Pharmaceutical Services (WST) is juggling mixed signals after recent updates on its business outlook. Investors now have to balance long-term growth drivers with fresh headwinds from a cyber incident, cost inflation, and a Scottsdale product line shutdown. Recent price action reflects that push and pull. The share price is up 9.89% over the past 90 days and 31.08% year to date, while the 1-year total shareholder return of 42.61% contrasts with a slightly negative 3-year total shareholder...

MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.

CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.

MMSI's portfolio, acquisitions, R&D strategy and WRAPSODY upside support growth, though tariffs, China pressure and OEM headwinds persist.

ANGO's NanoKnife growth, strong Med Tech momentum and solid Q3 results support holding the stock despite tariff and inflation pressures.

MMSI leans on therapeutic strength, an oncology acquisition and a new stent launch, but tariffs, OEM weakness and China pressure shadow 2026.

WST's HVP business and GLP-1 demand are driving growth, but can Annex 1 tailwinds and margin gains offset inflation and SmartDose risks?